ICB therapy-activated IFNγ-producing CD8+ T cells can also sensitize HCC to TKI therapy, and the combination of ICB and TKI represents a promising approach for the treatment of patients with HCC, particularly in the subgroup with GSDME expression. The gene discussed is CD8A; the disease is hepatocellular carcinoma.